Chang Yen-Yun, Ting Berne, Chen Daniel Tzu-Li, Hsu Wei-Ti, Lin Song-Chow, Kuo Chun-Yen, Wang Ming-Fu
Department of Food and Nutrition, Providence University, Taichung 433719, Taiwan.
Ph.D. Program for Aging, College of Medicine, China Medical University, Taichung 404333, Taiwan.
Healthcare (Basel). 2024 Feb 23;12(5):536. doi: 10.3390/healthcare12050536.
This study aimed to evaluate the efficacy of omega-3 fatty acid supplementation interventions in improving depression in patients with dementia. To achieve this objective, randomized controlled trials (RCTs) were identified from primary electronic databases, focusing on the relationship between omega-3 fatty acids and depression in patients with dementia. The primary outcome was the impact of omega-3 fatty acids on post-intervention depression in patients with dementia, with subgroup analyses conducted based on the type of intervention (docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) combination), duration of intervention (3 months, 6 months, 12 months, ≥24 months), cognitive function (ranging from mild cognitive impairment (MCI) to severe dementia), and daily dosage (high, medium, low, applicable to both DHA and EPA). The study has been duly registered with PROSPERO (registration ID: CRD42023408744). A meta-analysis of five studies (n = 517) included in nine systematic reviews showed that omega-3 supplementation had a non-significant trend toward affecting depressive symptoms in patients with dementia (standardized mean difference (SMD): 0.147; 95% confidence interval (CI): -0.324 to 0.049; = 0.141). Subgroup analyses revealed that DHA supplementation significantly reduced depressive symptoms (SMD: -0.247; = 0.039). There was no significant effect for high (SMD: -0.169; 95% CI: -0.454 to 0.116; = 0.246) or medium (SMD: -0.061; 95% CI: -0.228 to 0.105; = 0.470) doses of EPA. However, low doses of EPA were significantly effective (SMD: -0.953; 95% CI: -1.534 to -0.373; = 0.001), with notable improvements in patients with MCI (SMD: -0.934; < 0.001). The study concludes that omega-3 fatty acids, particularly through DHA supplementation, may alleviate depressive symptoms in patients with MCI. Given the limited sample size, further long-term RCTs are recommended to better understand the efficacy and optimal management of omega-3 supplementation in this population using different dosages.
本研究旨在评估补充ω-3脂肪酸干预措施对改善痴呆患者抑郁症状的疗效。为实现这一目标,从主要电子数据库中检索随机对照试验(RCT),重点关注ω-3脂肪酸与痴呆患者抑郁之间的关系。主要结局是ω-3脂肪酸对痴呆患者干预后抑郁的影响,并根据干预类型(二十二碳六烯酸(DHA)和二十碳五烯酸(EPA)联合使用)、干预持续时间(3个月、6个月、12个月、≥24个月)、认知功能(从轻度认知障碍(MCI)到重度痴呆)以及每日剂量(高、中、低,适用于DHA和EPA)进行亚组分析。该研究已在国际前瞻性系统评价注册库(PROSPERO)正式注册(注册号:CRD42023408744)。对纳入9项系统评价的5项研究(n = 517)进行的荟萃分析表明,补充ω-3脂肪酸对痴呆患者抑郁症状的影响无显著趋势(标准化均数差(SMD):0.147;95%置信区间(CI):-0.324至0.049;P = 0.141)。亚组分析显示,补充DHA可显著减轻抑郁症状(SMD:-0.247;P = 0.039)。高剂量(SMD:-0.169;95% CI:-0.454至0.116;P = 0.246)或中剂量(SMD:-0.061;95% CI:-0.228至0.105;P = 0.470)的EPA无显著效果。然而,低剂量的EPA有显著效果(SMD:-0.953;95% CI:-1.534至-0.373;P = 0.001),MCI患者有显著改善(SMD:-0.934;P < 0.001)。该研究得出结论,ω-3脂肪酸尤其是通过补充DHA,可能减轻MCI患者的抑郁症状。鉴于样本量有限,建议进一步开展长期RCT,以更好地了解不同剂量ω-3脂肪酸补充在该人群中的疗效和最佳管理方法。